Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 3, 2013, Pages 332-338

  Xu, Yiming ^a   Wu, Weizhen ^a   Wang, Liangsu ^a   Chintala, Madhu ^a   Plump, Andrew S ^a   Ogletree, Martin L ^a   Chen, Zhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

bivalirudin; dabigatran; heparin; hirudin; TEG; TGA

Indexed keywords

DABIGATRAN; HEPARIN; HIRUDIN; HIRULOG; THROMBIN;

ARTICLE; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; DRUG EFFECT; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOELASTOGRAPHY;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BIOLOGICAL ASSAY; BLOOD COAGULATION; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; WHOLE BLOOD COAGULATION TIME;

EID: 84875848381     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835e4219     Document Type: Article

References (31)

1. Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67:3-12.
2. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7:4-13.
3. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88:186-193. (Pubitemid 34873696)
4. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Adv Hematol 2012; 2012:856341.
5. Freedman MD. Pharmacodynamics, clinical indications, and adverse effects of heparin. J Clin Pharmacol 1992; 32:584-596.
6. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028-1040. (Pubitemid 41262337)
7. LaMuraglia GM, Houbballah R, Laposata M. The identification and management of heparin-induced thrombocytopenia in the vascular patient. J Vasc Surg 2012; 55:562-570.
8. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17:105-125. (Pubitemid 38780070)
9. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99:819-829. (Pubitemid 351705298)
10. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99:830-839.
11. AhmedS,LevinV,MalacoffR,MartinezMW.Dabigatran - anewchapterinanticoagulation. Cardiovasc Hematol Agents Med Chem 2012; 10:116-123.
12. Carrieri C, Galasso R, Semeraro F, Ammollo CT, Semeraro N, Colucci M. The role of thrombin activatable fibrinolysis inhibitor and factor XI in plateletmediated fibrinolysis resistance: a thromboelastographic study in whole blood. J Thromb Haemost 2011; 9:154-162.
13. McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 2011; 141:1410-1416.
14. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107:985-997.
15. Furugohri T,Sugiyama N, Morishima Y,Shibano T. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin- protein C system. Thromb Haemost 2011; 106:1076-1083.
16. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5:886-888. (Pubitemid 46563600)
17. Wolberg AS. Thrombin generation assays: understanding how the method influences the results. Thromb Res 2007; 119:663-665. (Pubitemid 46442869)
18. Van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142:889-903.
19. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98:155-162. (Pubitemid 47078782)
20. MacDonald SG, Luddington RJ. Critical factors contributing to the thromboelastography trace. Semin Thromb Hemost 2010; 36:712-722.
21. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4-15. (Pubitemid 37449290)
22. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001; 161:385-391. (Pubitemid 32116554)
23. He S, Blomback M, Bark N, Johnsson H, Wallen NH. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost 2010; 103:1076-1084.
24. Sorbera LA, Bozzo J, Castaner J. Dabigatran/dabigatran etexilate - prevention of DVT prevention of ischemic stroke thrombin inhibitor. Drug Future 2005; 30:877-885. (Pubitemid 43080761)
25. Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost 1996; 22:117-124. (Pubitemid 26239903)
26. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12(Suppl. F):27F-32F.
27. Furugohri T, Shiozaki Y, Muramatsu S, Honda Y, Matsumoto C, Isobe K, Sugiyama N. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur J Pharmacol 2005; 514:35-42. (Pubitemid 40692761)
28. Wagenvoord RJ, Deinum J, Elg M, Hemker HC. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulinthrombin. J Thromb Haemost 2010; 8:1281-1289.
29. Krishnaswamy A, Lincoff AM, Cannon CP. The use and limitations of unfractionated heparin. Crit Pathw Cardiol 2010; 9:35-40.
30. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101:4844-4846. (Pubitemid 36857744)
31. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72:381-386. (Pubitemid 24280776)